National Institutes of Health: Carcinoma, Renal Cell trials

The registry lists 123 Carcinoma, Renal Cell studies with National Institutes of Health as lead sponsor. 10 are open to participants now and 50 have results posted.

Phase 1 44Phase 2 79Phase 3 7No phase 7(a study in two phases counts in both)

Studies

Page 1 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Testing the Investigational Medication Pembrolizumab After Kidney Removal for Patients With Non-Clear Cell Renal Cell CarcinomaNot yet recruitingNCT07689240Phase 3
• Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT TrialRecruitingNCT07516366Phase 2
• Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)RecruitingNCT05665361Phase 1/2
• Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell CarcinomaRecruitingNCT05155033Phase 2
• Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney CancerRecruitingNCT04981509Phase 2
• A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract MalignanciesRecruitingNCT04923178
• Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsRecruitingNCT03866382Phase 2
• Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing CancersRecruitingNCT02830724Phase 1/2
• Use of Tracking Devices to Locate Abnormalities During Invasive ProceduresEnrolling by invitationNCT00102544Not applicable
• Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant DisordersRecruitingNCT00001238
• Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIVActive, not recruitingNCT04514484Phase 1Results posted
• Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal CarcinomaTerminatedNCT04150562Phase 2Results posted
• A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)Active, not recruitingNCT03595124Phase 2Results posted
• A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney CancerTerminatedNCT03165721Phase 2Results posted
• Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing NephrectomyActive, not recruitingNCT03055013Phase 3Results posted
• Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare TumorsActive, not recruitingNCT02867592Phase 2Results posted
• Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has ProgressedCompletedNCT02761057Phase 2Results posted
• Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal CancerTerminatedNCT02504892Phase 2Results posted
• Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell CarcinomaTerminatedNCT02495103Phase 1/2Results posted
• Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney CancersCompletedNCT02141490Phase 2Results posted
• A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell CancerCompletedNCT02019693Phase 2Results posted
• Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney CancerCompletedNCT01835158Phase 2Results posted
• Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney CancerCompletedNCT01727089Phase 2Results posted
• Imaging Studies of Kidney Cancer Using 18F-VM4-037TerminatedNCT01712685Phase 2Results posted
• Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by SurgeryCompletedNCT01688973Phase 2Results posted
• Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney CancerCompletedNCT01664182Phase 2Results posted
• Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After SurgeryActive, not recruitingNCT01575548Phase 3Results posted
• Vandetanib to Treat Advanced Kidney CancerTerminatedNCT01372813Phase 2Results posted
• Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney CancerTerminatedNCT01239342Phase 2Results posted
• Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line TherapyTerminatedNCT01198158Phase 3Results posted
• Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal CancerTerminatedNCT01160445Phase 2Results posted
• A Study of RO4929097 in Patients With Advanced Renal Cell Carcinoma That Have Failed Vascular Endothelial Growth Factor (VEGF)/Vascular Endothelial Growth Factor Receptor (VEGFR) TherapyCompletedNCT01141569Phase 2Results posted
• A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell CancerCompletedNCT01130519Phase 2Results posted
• Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney CancerActive, not recruitingNCT01038778Phase 1/2Results posted
• Randomized Pilot Study for the Treatment of Cutaneous Leiomyomas With Botulinum ToxinCompletedNCT00971620Phase 2Results posted
• Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney CancerCompletedNCT00923845Phase 2Results posted
• A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...CompletedNCT00923481Phase 2Results posted
• Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney CancerCompletedNCT00923130Phase 2Results posted
• Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney CancerTerminatedNCT00684996Phase 1/2Results posted
• Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic CancerTerminatedNCT00670748Phase 2Results posted
• Phase II Study of Vandetanib in Individuals With Kidney CancerCompletedNCT00566995Phase 2Results posted
• Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney CancerCompletedNCT00408902Phase 2Results posted
• Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney CancerCompletedNCT00378703Phase 2Results posted
• Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney CancerCompletedNCT00357760Phase 2Results posted
• Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By SurgeryCompletedNCT00326898Phase 3Results posted
• Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney CancerCompletedNCT00324870Phase 1/2Results posted
• Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney CancerTerminatedNCT00324740Phase 1/2Results posted
• AZD2171 in Treating Patients With Refractory Metastatic Kidney CancerTerminatedNCT00303862Phase 2Results posted
• Vorinostat in Treating Patients With Kidney CancerCompletedNCT00278395Phase 2Results posted
• Cediranib Maleate in Treating Patients With Recurrent or Metastatic Kidney Cancer That Cannot Be Removed By SurgeryCompletedNCT00227760Phase 2Results posted
• Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney CancerTerminatedNCT00126659Phase 2Results posted
• Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney CancerCompletedNCT00126594Phase 2Results posted
• Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney CancerCompletedNCT00126503Phase 1/2Results posted
• Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney CancerCompletedNCT00126490Phase 2Results posted
• Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney CancerCompletedNCT00121251Phase 1/2Results posted
• CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney CancerCompletedNCT00112840Phase 1/2Results posted
• Vaccine Treatment of Kidney CancerTerminatedNCT00089778Phase 2Results posted
• 17AAG to Treat Kidney Tumors in Von Hippel-Lindau DiseaseCompletedNCT00088374Phase 2Results posted
• BMS 247550 to Treat Kidney CancerCompletedNCT00030992Phase 2Results posted
• Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell CarcinomaTerminatedNCT00001703Phase 2Results posted
• Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 TrialActive, not recruitingNCT05411081Phase 2
• Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing SurgerySuspendedNCT04955808
• Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial MalignanciesWithdrawnNCT04648826Phase 1/2
• Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary MalignanciesActive, not recruitingNCT04235777Phase 1
• Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL StudyActive, not recruitingNCT04071223Phase 2
• Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE StudyActive, not recruitingNCT03793166Phase 3
• Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2Active, not recruitingNCT03284385Phase 2
• Nivolumab in Treating Patients With High-Risk Kidney Cancer Before SurgeryTerminatedNCT02595918Phase 1
• Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary TumorsActive, not recruitingNCT02496208Phase 1
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingNCT02465060Phase 2
• Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced CancerActive, not recruitingNCT02298959Phase 1
• Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck CancerCompletedNCT01727076Phase 1
• Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver DysfunctionCompletedNCT01638533Phase 1
• Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryCompletedNCT01548482Phase 1
• Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney CancerActive, not recruitingNCT01480154Phase 1
• Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid MalignanciesCompletedNCT01243359Phase 1
• Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid TumorsCompletedNCT01198184Phase 1
• A Pilot, Open-label Study of 18F-Fluciclatide PET/CT Imaging in the Evaluation of Anti-angiogenic Therapy in Solid TumorsWithdrawnNCT01176500Phase 1/2
• Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid TumorsCompletedNCT01131234Phase 1
• A Phase I Study of Intravenous Recombinant Human IL-15 in Adults With Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell CancerCompletedNCT01021059Phase 1
• Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung CancerTerminatedNCT00937482Phase 1
• A Phase 1, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612) in Advanced MalignanciesCompletedNCT00923520Phase 1
• Phase 1/2 Study of Metastatic Renal Cancer Using T-Cells Transduced With a T-Cell Receptor Which Recognizes TRAIL Bound to the DR4 ReceptorTerminatedNCT00923390Phase 1
• Part 2 of Phase 1 Study of GC1008 to Treat Advanced Melanoma (Part 2 Will Only Accept and Treat Patients With Advanced Malignant Melanoma)CompletedNCT00923169Phase 1
• Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral TherapyCompletedNCT00890747Phase 1
• Follow-Up Study of Kidney Cancer PatientsCompletedNCT00656955
• Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid TumorsCompletedNCT00499135Phase 1
• Ispinesib in Treating Patients With Metastatic or Unresectable Kidney CancerCompletedNCT00354250Phase 2
• AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By SurgeryCompletedNCT00348699Phase 1
• Case-Control Study of Renal Cell Cancer Among Caucasions and African Americans in the United StatesCompletedNCT00340457
• Positron Emission Tomography and CT Scan in Predicting Response in Patients With Metastatic Melanoma or Kidney Cancer Who Are Undergoing Cellular Adoptive Immunotherapy on a Surgery Branch Clinical TrialCompletedNCT00316901Phase 2
• Mechanism of Action of High-Dose IL-2 (Aldesleukin) in Metastatic Melanoma and Kidney CancerCompletedNCT00304460Phase 1
• Sorafenib in Treating Patients With Kidney Cancer That Has Spread to the BrainCompletedNCT00301847Phase 2
• Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By SurgeryCompletedNCT00217542Phase 1
• Ixabepilone in Treating Patients With Metastatic, Recurrent, or Unresectable Kidney CancerCompletedNCT00182702Phase 2
• Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid TumorsCompletedNCT00112476Phase 1
• Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung CancerCompletedNCT00101348Phase 1/2
• Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney CancerCompletedNCT00101114Phase 2
• Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney CancerTerminatedNCT00098618Phase 2
• Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous TreatmentCompletedNCT00091182Phase 2